

# Jeffrey R Curtis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6658027/publications.pdf>

Version: 2024-02-01

334  
papers

22,089  
citations

15504

65  
h-index

11308

136  
g-index

338  
all docs

338  
docs citations

338  
times ranked

19508  
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1-26.	5.6	1,880
2	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 625-639.	3.4	1,413
3	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 59, 762-784.	6.7	1,311
4	The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine. Journal of Bone and Mineral Research, 2014, 29, 2520-2526.	2.8	1,305
5	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 1-25.	3.4	890
6	Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis and Rheumatism, 2006, 55, 420-426.	6.7	448
7	Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor $\pm$ antagonists. Arthritis and Rheumatism, 2007, 56, 1125-1133.	6.7	351
8	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis and Rheumatism, 2012, 64, 2824-2835.	6.7	325
9	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Annals of the Rheumatic Diseases, 2017, 76, 1253-1262.	0.9	316
10	Initiation of Tumor Necrosis Factor- $\pm$ Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. JAMA - Journal of the American Medical Association, 2011, 306, 2331-9.	7.4	305
11	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 576-582.	0.9	304
12	High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 785-791.	0.9	269
13	Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies. Journal of Rheumatology, 2014, 41, 837-852.	2.0	264
14	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Annals of the Rheumatic Diseases, 2010, 69, 1920-1925.	0.9	255
15	Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases. JAMA - Journal of the American Medical Association, 2012, 308, 43-9.	7.4	246
16	Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical Therapeutics, 2011, 33, 679-707.	2.5	241
17	Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Research and Therapy, 2019, 21, 89.	3.5	232
18	Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1843-1847.	0.9	215

#	ARTICLE	IF	CITATIONS
19	Obesity and response to anti-tumor necrosis factor- $\alpha$ agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0195123.	2.5	196
20	Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 644-649.	0.9	183
21	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. <i>Arthritis and Rheumatology</i> , 2017, 69, 1960-1968.	5.6	182
22	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	3.4	161
23	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. <i>Arthritis Care and Research</i> , 2019, 71, 1540-1555.	3.4	157
24	Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. <i>Arthritis and Rheumatology</i> , 2016, 68, 2328-2337.	5.6	150
25	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012, 64, 1794-1803.	3.4	149
26	Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e60635.	2.5	146
27	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. <i>Arthritis and Rheumatology</i> , 2021, 73, 1093-1107.	5.6	146
28	Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. <i>Arthritis and Rheumatology</i> , 2016, 68, 2612-2617.	5.6	138
29	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016, 68, 56-66.	5.6	136
30	Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 831-841.	0.9	135
31	Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1400-1413.	0.9	132
32	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016, 152, 164.	4.1	131
33	The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1301-1308.	0.9	126
34	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e60-e75.	5.6	126
35	Death, Debility, and Destitution Following Hip Fracture. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 346-353.	3.6	125
36	Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1430-1438.	6.7	124

#	ARTICLE	IF	CITATIONS
37	Recent trends in hip fracture rates by race/ethnicity among older US adults. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2325-2332.	2.8	121
38	Longitudinal Trends in Use of Bone Mass Measurement Among Older Americans, 1999-2005. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1061-1067.	2.8	115
39	Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 611-619.	2.2	113
40	A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. <i>Gastroenterology</i> , 2021, 161, 837-852.e9.	1.3	113
41	Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor $\pm$ agents, a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 319.	3.5	106
42	Population-Based Fracture Risk Assessment and Osteoporosis Treatment Disparities by Race and Gender. <i>Journal of General Internal Medicine</i> , 2009, 24, 956-962.	2.6	101
43	Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1435-1441.	2.8	100
44	Identification and Validation of Vertebral Compression Fractures Using Administrative Claims Data. <i>Medical Care</i> , 2009, 47, 69-72.	2.4	100
45	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1942-1948.	0.9	100
46	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020, 6, e001395.	3.8	100
47	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 489-497.	3.4	99
48	Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor- $\gamma$ -Directed Therapy for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 405-417.	0.4	99
49	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1401-1406.	0.9	98
50	Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2020, 173, 870-878.	3.9	97
51	Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2020, 72, 561-576.	3.4	96
52	Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 842-849.	1.9	94
53	Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF- $\gamma$ Blockade with Nonbiologic DMARDs. <i>American Journal of Medicine</i> , 2013, 126, 730.e9-730.e17.	1.5	94
54	Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy. <i>Arthritis Care and Research</i> , 2015, 67, 731-736.	3.4	94

#	ARTICLE	IF	CITATIONS
55	The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. <i>Arthritis Research and Therapy</i> , 2011, 13, R174.	3.5	92
56	Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1813-1818.	0.9	90
57	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.9	89
58	Improving the Prediction of Medication Compliance. <i>Medical Care</i> , 2009, 47, 334-341.	2.4	87
59	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1065-1071.	0.9	79
60	Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users. <i>Archives of Internal Medicine</i> , 2007, 167, 591.	3.8	78
61	Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2016, 43, 1997-2009.	2.0	78
62	Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1255-1265.	0.9	77
63	The incidence of gastrointestinal perforations among rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2011, 63, 346-351.	6.7	71
64	Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. <i>Arthritis Care and Research</i> , 2019, 71, 1249-1254.	3.4	71
65	Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Patients with Gout in an Integrated Healthcare System. <i>Journal of Rheumatology</i> , 2015, 42, 504-512.	2.0	69
66	Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. <i>Arthritis Care and Research</i> , 2015, 67, 1671-1678.	3.4	67
67	Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2017, 69, 1845-1854.	3.4	66
68	Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R155.	3.5	65
69	Linkage of a Deidentified United States Rheumatoid Arthritis Registry With Administrative Data to Facilitate Comparative Effectiveness Research. <i>Arthritis Care and Research</i> , 2014, 66, 1790-1798.	3.4	65
70	Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1293-1301.e5.	4.4	65
71	Association between anti-TNF therapy and interstitial lung disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 394-402.	1.9	64
72	Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. <i>Special Care in Dentistry</i> , 2010, 30, 77-82.	0.8	63

#	ARTICLE	IF	CITATIONS
73	Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 341-347.	0.9	63
74	Identifying types of nursing facility stays using medicare claims data: an algorithm and validation. <i>Health Services and Outcomes Research Methodology</i> , 2010, 10, 100-110.	1.8	62
75	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 430-436.	0.9	61
76	Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 285-291.	0.9	61
77	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e30-e45.	5.6	61
78	Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 710-718.	1.9	59
79	Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1819-1828.	3.4	59
80	Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. <i>Arthritis and Rheumatism</i> , 2012, 64, 630-638.	6.7	59
81	Increased pretreatment serum IFN- $\gamma$ /IL-6 ratio predicts non-response to tumour necrosis factor $\alpha$ inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.9	59
82	Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis and Rheumatology</i> , 2017, 69, 1733-1740.	5.6	59
83	Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 231.	1.9	58
84	Is Withholding Osteoporosis Medication After Fracture Sometimes Rational? A Comparison of the Risk for Second Fracture Versus Death. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 584-591.	2.5	57
85	Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. <i>Chest</i> , 2018, 154, 1311-1320.	0.8	57
86	Advancing the Science and Practice of Medication Adherence. <i>Journal of General Internal Medicine</i> , 2018, 33, 216-222.	2.6	57
87	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2021, 48, 603-607.	2.0	56
88	Placebo Adherence, Clinical Outcomes, and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. <i>Medical Care</i> , 2011, 49, 427-435.	2.4	55
89	Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 76.	1.7	55
90	Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids: clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. <i>Arthritis Research and Therapy</i> , 2019, 21, 207.	3.5	54

#	ARTICLE	IF	CITATIONS
91	Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions. <i>Drugs and Aging</i> , 2012, 29, 549-564.	2.7	53
92	Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 858-864.	2.8	53
93	Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2086-2095.	2.8	53
94	Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2019, 71, 1004-1018.	3.4	53
95	Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab. <i>Arthritis and Rheumatology</i> , 2015, 67, 1456-1464.	5.6	51
96	Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus low-risk rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012, 64, 1480-1489.	3.4	49
97	Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program. <i>Arthritis Care and Research</i> , 2013, 65, 1743-1751.	3.4	49
98	Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. <i>American Journal of Medicine</i> , 2019, 132, 354-361.	1.5	49
99	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. <i>Arthritis and Rheumatology</i> , 2022, 74, e21-e36.	5.6	49
100	Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. <i>Arthritis Care and Research</i> , 2012, 64, 1282-1291.	3.4	48
101	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1012-1016.	0.9	48
102	Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1881-1888.	2.8	47
103	Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 60.	3.5	46
104	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1522-1529.	0.9	46
105	The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 683-688.	2.8	45
106	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. <i>RMD Open</i> , 2019, 5, e000942.	3.8	45
107	What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1500-1503.	2.8	44
108	The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1798-1807.	2.8	44

#	ARTICLE	IF	CITATIONS
109	Adaptation of Bayesian Data Mining Algorithms to Longitudinal Claims Data. <i>Medical Care</i> , 2008, 46, 969-975.	2.4	43
110	The delivery of evidence-based preventive care for older Americans with arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R144.	3.5	43
111	Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort. <i>Arthritis Care and Research</i> , 2011, 63, 1672-1679.	3.4	43
112	Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 381-388.	3.4	43
113	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	3.4	43
114	Impact of Biologic Agents With and Without Concomitant Methotrexate and at Reduced Doses in Older Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 624-632.	3.4	41
115	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 1.	3.5	41
116	Osteoporosis Care in the United States After Declines in Reimbursements for DXA. <i>Journal of Clinical Densitometry</i> , 2010, 13, 352-360.	1.2	40
117	Commentary: The Five Ws of a Fracture Liaison Service: Why, Who, What, Where, and How? In Osteoporosis, We Reap What We Sow. <i>Current Osteoporosis Reports</i> , 2013, 11, 365-368.	3.6	38
118	Osteoporosis medication adherence: Physician perceptions vs. patients' utilization. <i>Bone</i> , 2013, 55, 1-6.	2.9	37
119	Validation Study of Medicare Claims to Identify Older US Adults With CKD Using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 249-258.	1.9	37
120	Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. <i>Hypertension</i> , 2020, 75, 246-256.	2.7	37
121	Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population. <i>Arthritis Care and Research</i> , 2012, 64, 1054-1060.	3.4	36
122	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.8	36
123	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.	3.4	35
124	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 286-292.	0.9	35
125	Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. <i>Arthritis Research and Therapy</i> , 2021, 23, 53.	3.5	35
126	Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. <i>Arthritis Care and Research</i> , 2010, 62, 101-107.	3.4	34



#	ARTICLE	IF	CITATIONS
127	Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2010, 62, 1481-1488.	3.4	34
128	Patient perspectives on achieving T2T goals: A critical examination of patient reported outcomes. <i>Arthritis Care and Research</i> , 2013, 65, n/a-n/a.	3.4	34
129	Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2351-2358.	5.6	34
130	Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study. <i>Arthritis Care and Research</i> , 2019, 71, 80-87.	3.4	34
131	Tumor necrosis factor inhibitors and infection complications. <i>Current Rheumatology Reports</i> , 2008, 10, 383-389.	4.7	33
132	Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year. <i>Arthritis Care and Research</i> , 2012, 64, 658-667.	3.4	33
133	Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States. <i>Arthritis Care and Research</i> , 2014, 66, 1604-1611.	3.4	33
134	PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 14.	1.9	33
135	Digital Interventions to Build a Patient Registry for Rheumatology Research. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 173-186.	1.9	33
136	Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. <i>Osteoporosis International</i> , 2020, 31, 1299-1304.	3.1	33
137	Association of Intact Parathyroid Hormone Levels with Subsequent Hip BMD Loss: The Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1937-1944.	3.6	32
138	Vaccinations for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 431.	4.7	32
139	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015, 10, e0135327.	2.5	32
140	Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 313-322.	3.4	32
141	Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 40-44.	2.0	32
142	Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. <i>Arthritis Care and Research</i> , 2021, 73, 1153-1161.	3.4	32
143	Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 206-212.	0.9	31
144	Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions. <i>Medical Care</i> , 2018, 56, S16-S21.	2.4	31

#	ARTICLE	IF	CITATIONS
145	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	2.0	31
146	Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. <i>European Respiratory Journal</i> , 2019, 54, 1801896.	6.7	31
147	Bridging the Osteoporosis Quality Chasm. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 3-7.	2.8	30
148	DXA Utilization Between 2006 and 2012 in Commercially Insured Younger Postmenopausal Women. <i>Journal of Clinical Densitometry</i> , 2015, 18, 145-149.	1.2	30
149	Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 263-274.	0.8	30
150	Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1526-1534.	3.4	29
151	SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269-271.	0.9	29
152	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021, 73, 759-768.	5.6	29
153	Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. , 2016, 20, 15-151.		28
154	Estimating Effectiveness and Cost of Biologics for Rheumatoid Arthritis: Application of a Validated Algorithm to Commercial Insurance Claims. <i>Clinical Therapeutics</i> , 2014, 36, 996-1004.	2.5	27
155	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1751-1757.	3.4	27
156	Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. <i>Journal of Rheumatology</i> , 2017, 44, 1083-1087.	2.0	27
157	Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 113.	1.9	26
158	Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Commercially Insured Population. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 318-328.	0.9	26
159	Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 707-715.	1.9	26
160	Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 827-835.	1.9	26
161	Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. <i>BMC Cancer</i> , 2016, 16, 381.	2.6	26
162	The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 695-703.	1.3	26

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 390-400.	0.8	26
164	Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1935-1943.	2.0	25
165	Validity of Privacy-Protecting Analytical Methods That Use Only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks. <i>American Journal of Epidemiology</i> , 2019, 188, 709-723.	3.4	25
166	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 206-213.	0.9	25
167	Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2017, 69, 439-446.	5.6	24
168	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. <i>Journal of Rheumatology</i> , 2022, 49, 320-329.	2.0	24
169	Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. <i>Current Medical Research and Opinion</i> , 2011, 27, 71-78.	1.9	23
170	Optimal Use of Available Claims to Identify a Medicare Population Free of Coronary Heart Disease. <i>American Journal of Epidemiology</i> , 2015, 182, 808-819.	3.4	23
171	Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 386-392.	0.9	23
172	Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology. <i>Arthritis Care and Research</i> , 2020, 72, 166-175.	3.4	23
173	Primary Prophylaxis for <i>Pneumocystis jirovecii</i> Pneumonia in Patients Receiving Rituximab. <i>Chest</i> , 2022, 161, 1201-1210.	0.8	23
174	Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. <i>Journal of Medical Economics</i> , 2014, 17, 555-566.	2.1	22
175	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. <i>Clinical Rheumatology</i> , 2018, 37, 2331-2340.	2.2	22
176	Importance of Recent Fracture as Predictor of Imminent Fracture Risk. <i>Current Osteoporosis Reports</i> , 2018, 16, 738-745.	3.6	22
177	Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. <i>RMD Open</i> , 2019, 5, e001013.	3.8	22
178	Racial Disparities Exist in Outcomes After Major Fragility Fractures. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1803-1810.	2.6	22
179	Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System. <i>Arthritis Care and Research</i> , 2013, 65, 235-243.	3.4	21
180	A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1429-1430.	0.9	21

#	ARTICLE	IF	CITATIONS
181	A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. <i>Arthritis and Rheumatology</i> , 2015, 67, 3104-3112.	5.6	21
182	Studies with herpes zoster vaccines in immune compromised patients. <i>Expert Review of Vaccines</i> , 2017, 16, 1217-1230.	4.4	21
183	Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available. <i>Arthritis Research and Therapy</i> , 2020, 22, 242.	3.5	21
184	Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 86.	3.5	21
185	Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1150-1158.	1.9	20
186	Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising. <i>Arthritis Research and Therapy</i> , 2017, 19, 48.	3.5	20
187	Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes. <i>Arthritis Care and Research</i> , 2019, 71, 1224-1233.	3.4	20
188	Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1394-1408.	1.9	20
189	Prevention and treatment of glucocorticoid-induced osteoporosis. <i>Current Osteoporosis Reports</i> , 2007, 5, 14-21.	3.6	19
190	Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. <i>Arthritis Care and Research</i> , 2012, 64, 1855-1863.	3.4	19
191	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 310-319.	1.9	19
192	Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 472-477.	3.4	19
193	Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. <i>Arthritis Care and Research</i> , 2019, 71, 1326-1335.	3.4	19
194	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2021, 3, 381-389.	2.1	19
195	Ethnic Variations in the Prevalence of Metabolic Bone Disease among HIV-Positive Patients with Lipodystrophy. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 125-131.	1.1	18
196	Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 137-143.	3.4	18
197	Usability and Workflow Evaluation of the Rheumatoid Disease Activity (READY). <i>Applied Clinical Informatics</i> , 2016, 07, 1007-1024.	1.7	18
198	Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians. <i>Drug Safety</i> , 2018, 41, 545-553.	3.2	18

#	ARTICLE	IF	CITATIONS
199	Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. <i>Current Medical Research and Opinion</i> , 2019, 35, 1483-1493.	1.9	18
200	The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 1510-1518.	3.9	18
201	The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1447-1457.	2.4	17
202	Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2017, 39, 1680-1694.e2.	2.5	17
203	Assessing a novel way to measure step count while walking using a custom mobile phone application. <i>PLoS ONE</i> , 2018, 13, e0206828.	2.5	17
204	Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 228-236.	3.4	17
205	Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives. <i>Arthritis Care and Research</i> , 2022, 74, 588-597.	3.4	17
206	Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 573-580.	0.9	17
207	Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2014, 41, 2078-2084.	2.0	16
208	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2019, 37, 829-843.	3.3	16
209	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	1.9	16
210	Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 1392-1403.	3.4	16
211	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- $\pm$ Inhibitors: The NETWORK-004 Prospective Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1159-1176.	2.3	16
212	Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. <i>Arthritis Care and Research</i> , 2022, 74, 733-740.	3.4	16
213	Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning. <i>Arthritis Care and Research</i> , 2023, 75, 220-230.	3.4	16
214	Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis Care and Research</i> , 2019, 71, 1593-1599.	3.4	15
215	Physical activity measured using wearable activity tracking devices associated with gout flares. <i>Arthritis Research and Therapy</i> , 2020, 22, 181.	3.5	15
216	Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study. <i>JMIR Research Protocols</i> , 2019, 8, e14665.	1.0	15

#	ARTICLE	IF	CITATIONS
217	Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level data. <i>Arthritis and Rheumatism</i> , 2011, 63, 2203-2208.	6.7	14
218	A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2603-2610.	2.8	14
219	Identifying newly approved medications in Medicare claims data: a case study using tocilizumab. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1214-1221.	1.9	14
220	A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. <i>Arthritis Research and Therapy</i> , 2017, 19, 215.	3.5	14
221	Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes Mellitus?. <i>Arthritis Care and Research</i> , 2018, 70, 1694-1699.	3.4	14
222	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 594-602.	4.4	14
223	Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 282.	3.5	14
224	Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids. <i>Arthritis Care and Research</i> , 2021, 73, 1597-1605.	3.4	14
225	Swallowing difficulties from "DISH-phagia". <i>Journal of Rheumatology</i> , 2004, 31, 2526-7.	2.0	14
226	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 136.	3.5	13
227	Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. <i>PLoS ONE</i> , 2016, 11, e0149781.	2.5	13
228	Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology. <i>Arthritis Care and Research</i> , 2020, 72, 553-560.	3.4	13
229	Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 478-487.	2.8	13
230	Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 854-863.	1.9	13
231	Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry. <i>Arthritis Research and Therapy</i> , 2020, 22, 4.	3.5	13
232	Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. <i>Patient</i> , 2021, 14, 699-710.	2.7	13
233	Republished: The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. <i>Postgraduate Medical Journal</i> , 2014, 90, 722-729.	1.8	12
234	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2016, 14, 49.	2.1	12

#	ARTICLE	IF	CITATIONS
235	Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study. <i>Contemporary Clinical Trials</i> , 2016, 50, 106-115.	1.8	12
236	Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2016, 43, 1027-1029.	2.0	12
237	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017, 44, 1894-1898.	2.0	12
238	Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept. <i>Patient</i> , 2018, 11, 361-369.	2.7	12
239	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	3.4	12
240	Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2021, 48, 804-812.	2.0	12
241	Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 292-298.	3.4	12
242	Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1239-1242.	2.0	12
243	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021, 41, 1755-1761.	3.0	12
244	Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry. <i>Rheumatology and Therapy</i> , 2022, 9, 207-221.	2.3	12
245	Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 925-936.	1.9	11
246	Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 988-995.	3.4	11
247	Tough Choices: Exploring Medication Decision-Making During Pregnancy and Lactation Among Women With Inflammatory Arthritis. <i>ACR Open Rheumatology</i> , 2021, 3, 475-483.	2.1	11
248	Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 276.	3.5	10
249	Pregnancy, Periods, and "The Pill": Exploring the Reproductive Experiences of Women with Inflammatory Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 125-132.	2.1	10
250	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1114-1124.	3.4	10
251	Secular Trends in the Incidence of Hip Fracture Among Nursing Home Residents. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1668-1675.	2.8	10
252	Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. <i>ACR Open Rheumatology</i> , 2021, 3, 17-24.	2.1	10

#	ARTICLE	IF	CITATIONS
253	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2021, 8, 1661-1675.	2.3	10
254	Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the COVID-19 Pandemic. <i>Arthritis Care and Research</i> , 2022, 74, 1049-1057.	3.4	10
255	A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs. <i>American Journal of Managed Care</i> , 2005, 11, 537-43.	1.1	10
256	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. <i>RMD Open</i> , 2022, 8, e002103.	3.8	10
257	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2017, 44, 565-570.	2.0	9
258	Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 79.	3.5	9
259	Tools and Methods for Real-World Evidence Generation. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 275-289.	1.9	9
260	Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 1207-1212.	2.2	9
261	Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 933-941.	3.4	9
262	COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings. <i>Arthritis and Rheumatology</i> , 2022, 74, 1091-1092.	5.6	9
263	Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare Beneficiaries. <i>Journal of Clinical Densitometry</i> , 2008, 11, 568-574.	1.2	8
264	Validity of physician-reported hospitalized infections in a US arthritis registry. <i>Rheumatology</i> , 2009, 48, 1269-1272.	1.9	8
265	Improving osteoporosis care in high-risk home health patients through a high-intensity intervention. <i>Contemporary Clinical Trials</i> , 2012, 33, 206-212.	1.8	8
266	Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 128-137.	0.7	8
267	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 757-769.	1.9	8
268	Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 770-777.	1.9	8
269	Real-world switch patterns and healthcare costs in biologic-naïve psoriasis patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 767-779.	1.4	8
270	Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 14607.	3.3	8



#	ARTICLE	IF	CITATIONS
271	Patterns of Tumor Necrosis Factor Inhibitor ( TNF i) Biosimilar Use Across United States Rheumatology Practices. ACR Open Rheumatology, 2020, 2, 79-83.	2.1	8
272	Use of health plan combined with registry data to predict clinical trial recruitment. Clinical Trials, 2014, 11, 96-101.	1.6	7
273	An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users. Journal of Rheumatology, 2015, 42, 1478-1483.	2.0	7
274	Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?. BMC Rheumatology, 2019, 3, 36.	1.6	7
275	Evaluation of the Effect of Diabetes on Rheumatoid Arthritisâ€related Outcomes in an Electronic Health Recordâ€based Rheumatology Registry. Journal of Rheumatology, 2021, 48, 992-1001.	2.0	7
276	TNFi Cycling Versus Changing Mechanism of Action in TNFiâ€Experienced Patients: Result of the Corona CERTAIN Comparative Effectiveness Study. ACR Open Rheumatology, 2022, 4, 65-73.	2.1	7
277	Fractures and mortality in relation to different osteoporosis treatments. Clinical and Experimental Rheumatology, 2015, 33, 302-9.	0.8	7
278	Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatology and Therapy, 2022, 9, 243-263.	2.3	7
279	The Economic Benefit of Remission for Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 1329-1345.	2.3	7
280	Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data. Arthritis Care and Research, 2018, 70, 1541-1545.	3.4	6
281	Development of algorithms for identifying fatal cardiovascular disease in <scp>Medicare</scp> claims. Pharmacoepidemiology and Drug Safety, 2018, 27, 740-750.	1.9	6
282	Defining and characterizing sustained remission in patients with rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 885-893.	2.2	6
283	Assessing a novel way to measure three common rehabilitation outcome measures using a custom mobile phone application. Gait and Posture, 2019, 73, 246-250.	1.4	6
284	Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis. BMC Rheumatology, 2020, 4, 14.	1.6	6
285	Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. BMC Rheumatology, 2020, 4, 26.	1.6	6
286	Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients. Osteoarthritis and Cartilage, 2020, 28, 917-923.	1.3	6
287	Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. Arthritis Care and Research, 2023, 75, 231-239.	3.4	6
288	The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw. PLoS ONE, 2015, 10, e0131601.	2.5	6

#	ARTICLE	IF	CITATIONS
289	Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 2.	3.5	6
290	Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor- $\epsilon$ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 101-109.	3.1	6
291	Trends in Hospitalization Rates, Major Causes of Hospitalization, and In-Hospital Mortality in Rheumatoid Arthritis in the United States From 2000 to 2014. <i>ACR Open Rheumatology</i> , 2020, 2, 715-724.	2.1	5
292	Enhancing Patient Understanding of Medication Risks and Benefits. <i>Arthritis Care and Research</i> , 2020, , .	3.4	5
293	Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study. <i>Scientific Reports</i> , 2020, 10, 3102.	3.3	5
294	Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. <i>Arthritis Care and Research</i> , 2021, 73, 289-295.	3.4	5
295	Risk of Serious Infection With Low-dose Glucocorticoids in Patients With Rheumatoid Arthritis. <i>Epidemiology</i> , 2022, 33, 65-74.	2.7	5
296	Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset. <i>ACR Open Rheumatology</i> , 2022, 4, 300-305.	2.1	5
297	Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US. <i>Arthritis and Rheumatology</i> , 2022, 74, 1833-1841.	5.6	5
298	Evaluating and improving the quality of care in rheumatic disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 429-439.	1.4	4
299	Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 285.	3.5	4
300	Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002-2017. <i>RMD Open</i> , 2020, 6, e001241.	3.8	4
301	Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment. <i>Clinical Rheumatology</i> , 2021, 40, 2419-2426.	2.2	4
302	Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. <i>International Immunopharmacology</i> , 2021, 91, 107260.	3.8	4
303	The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases. <i>ACR Open Rheumatology</i> , 2021, 3, 743-752.	2.1	4
304	Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. <i>PLoS ONE</i> , 2020, 15, e0244239.	2.5	4
305	Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. <i>Rheumatology and Therapy</i> , 2022, 9, 509-520.	2.3	4
306	Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis. <i>Gastroenterology</i> , 2018, 154, 748-750.	1.3	3

#	ARTICLE	IF	CITATIONS
307	An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches. , 2018, 22, 17-101.		3
308	Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States. Journal of Rheumatology, 2019, 46, 237-244.	2.0	3
309	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3 <sup>rd</sup> Methodology Applied to Two Active Comparator Trials. Arthritis Care and Research, 2019, 71, 319-322.	3.4	3
310	Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. Journal of Bone and Mineral Research, 2020, 35, 996-997.	2.8	3
311	Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open, 2021, 7, e001399.	3.8	3
312	Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death. Journal of Rheumatology, 2021, 48, 1745-1753.	2.0	3
313	Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. Rheumatology and Therapy, 2021, 8, 1383-1391.	2.3	3
314	Protocol for the pilot randomized trial of the CARdiovascular Risk assEssment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention. Pilot and Feasibility Studies, 2022, 8, 84.	1.2	3
315	Rheumatologist and Patient Mental Models for Treatment of Rheumatoid Arthritis Help Explain Low Treatment Target Rates. ACR Open Rheumatology, 2022, 4, 700-710.	2.1	3
316	Improving medical record retrieval for validation studies in Medicare data. Pharmacoepidemiology and Drug Safety, 2017, 26, 393-401.	1.9	2
317	Harnessing health plan enrollee data to boost membership in patient-powered research networks. BMC Health Services Research, 2020, 20, 462.	2.2	2
318	Reply. Arthritis and Rheumatology, 2021, 73, 1769-1770.	5.6	2
319	Development and validation of the Methotrexate Experience Questionnaire, a new methotrexate oral treatment adherence tool in rheumatoid arthritis. Journal of Patient-Reported Outcomes, 2021, 5, 69.	1.9	2
320	Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. ACR Open Rheumatology, 2021, , .	2.1	2
321	COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination. Journal of Rheumatology, 2022, , jrheum.211319.	2.0	2
322	Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib. ACR Open Rheumatology, 2022, 4, 254-258.	2.1	2
323	Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib+Oral Methotrexate Combination. Clinical Therapeutics, 2022, , .	2.5	2
324	Epidemiologic Research of Invasive Fungal Infections Using Large Healthcare Databases. Current Fungal Infection Reports, 2013, 7, 320-325.	2.6	1

#	ARTICLE	IF	CITATIONS
325	Reply. Arthritis and Rheumatology, 2018, 70, 795-796.	5.6	1
326	Reply. Arthritis and Rheumatology, 2018, 70, 320-320.	5.6	1
327	The promise and perils of "Big Data": focus on spondyloarthritis. Current Opinion in Rheumatology, 2019, 31, 355-361.	4.3	1
328	Response to: "Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?" by Suyama and Okada. Annals of the Rheumatic Diseases, 2019, 78, e18-e18.	0.9	1
329	Evaluation of an Intervention to Support <scp>Patient-Rheumatologist</scp> Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A <scp>Proof-of-Principle</scp> Study. ACR Open Rheumatology, 2022, 4, 279-287.	2.1	1
330	The Interface Between Digital Health and Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xv-xvi.	1.9	0
331	Reply. Arthritis Care and Research, 2020, 72, 736-738.	3.4	0
332	Reply. Arthritis and Rheumatology, 2021, 73, 1771-1772.	5.6	0
333	Association between chronic obstructive pulmonary disease, smoking, and interstitial lung disease onset in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
334	P204 Filgotinib demonstrates clinical efficacy in rheumatoid arthritis independent of smoking status: a post-hoc subgroup analysis of three Phase 3 clinical trials. Rheumatology, 2022, 61, .	1.9	0